This is an observational study aiming at collecting efficacy and safety data on the use of SVd outside clinical trials, for the treatment of adult patients with MM who have received 1-3 prior line of therapy.
A minimum of 159 patients is required. Overall study duration is estimated in 36 months.
Age equal to or greater than 18 years old at the time of SVd initiation
Signed informed consent (if applicable).
Diagnosis of symptomatic MM, as defined by the International Myeloma Working Group (IMWG) criteria.
Relapse after one to three lines of therapy.
None
this study will include patients who will start SVD treatment during the study enrolment period or who received at least one dose of the treatment according to AIFA authorization before the study inclusion date.
Case-only
Prospective
Not listed
SdV therapy effectiveness in terms of Progression Free Survival
to describe the effectiveness of the use of SVd therapy outside clinical trials in terms of Progression free survival after 12 months from the start of treatment
Click on the lead sponsor to view all of their trials.
